Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 27

Results For "PIP"

609 News Found

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn
News | June 12, 2023

Novartis to acquire Chinook Therapeutics for US$ 3.2 bn

Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease


Asence Pharma commences new plant at Ranoli, Vadodara
News | June 10, 2023

Asence Pharma commences new plant at Ranoli, Vadodara

The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement


Evonik launches next-generation peptide for biopharma applications
News | June 02, 2023

Evonik launches next-generation peptide for biopharma applications

One thousand times more soluble than L-cystine at neutral pH


Capnopharm receives CE certification for its new CapnoPen technology
News | May 31, 2023

Capnopharm receives CE certification for its new CapnoPen technology

Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745


Hikal posts FY23 PAT at Rs. 36 Cr
News | May 30, 2023

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22


JB Pharma records revenue growth of 22% to Rs. 762 Cr
News | May 25, 2023

JB Pharma records revenue growth of 22% to Rs. 762 Cr

Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23


Freenome acquires global immunodiagnostics developer Oncimmune
News | May 23, 2023

Freenome acquires global immunodiagnostics developer Oncimmune

Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection


Venus Remedies recognized for R&D excellence by DSIR
News | May 19, 2023

Venus Remedies recognized for R&D excellence by DSIR

Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions


Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr
News | May 13, 2023

Cipla reports Q4 FY 23 consolidated PAT at Rs. 525.65 Cr

Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023


Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform
News | May 05, 2023

Nouscom reaches clinical phase II using ProBioGen’s AGE1.CR.pIX production platform

Nous-209 has been developed using the Nouscom's viral vector platform